KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abbott Laboratories (ABT) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to 18.09%.

  • Abbott Laboratories' EBITDA Margin rose 6100.0% to 18.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.59%, marking a year-over-year increase of 13500.0%. This contributed to the annual value of 16.27% for FY2024, which is 1200.0% up from last year.
  • As of Q3 2025, Abbott Laboratories' EBITDA Margin stood at 18.09%, which was up 6100.0% from 18.42% recorded in Q2 2025.
  • In the past 5 years, Abbott Laboratories' EBITDA Margin registered a high of 24.48% during Q1 2022, and its lowest value of 12.92% during Q4 2022.
  • Over the past 5 years, Abbott Laboratories' median EBITDA Margin value was 17.38% (recorded in 2023), while the average stood at 17.66%.
  • Per our database at Business Quant, Abbott Laboratories' EBITDA Margin skyrocketed by 103600bps in 2021 and then crashed by -90000bps in 2023.
  • Abbott Laboratories' EBITDA Margin (Quarter) stood at 20.74% in 2021, then crashed by -38bps to 12.92% in 2022, then soared by 35bps to 17.38% in 2023, then increased by 0bps to 17.41% in 2024, then increased by 4bps to 18.09% in 2025.
  • Its EBITDA Margin was 18.09% in Q3 2025, compared to 18.42% in Q2 2025 and 16.34% in Q1 2025.